Elasomeran

肿瘤治疗正在进入精准免疫时代。继mRNA技术凭借COVID-19疫苗实现全球规模化应用后，越来越多创新型生物医药企业开始探索其在肿瘤治疗领域的全新价值——个性化肿瘤疫苗（PCV）。这种新型免疫疗法并非针对所有患者设计“一种疫苗”，而是基于每位患者肿瘤基因特征，通过下一代测序（NGS）和生物信息学分析，识别患者特异性的肿瘤新抗原，并设计能够精准激活免疫系统的个体化疫苗。其核心机制是诱导抗原特异性T细胞免疫反应，使患者自身免疫系统能够识别并清除肿瘤细胞，同时最大程度降低对正常组织的影响。 近年来，个性化肿瘤疫苗的发展正在从概念验证逐步迈向临床应用阶段。其中，Moderna与默沙东联合开发的个体化mRNA新抗原疗法intismeran autogene（V940/mRNA-4157）成为该领域最受关注的候选产品之一。该疗法与PD-1免疫检查点抑制剂Keytruda（帕博利珠单抗）联合使用，用于接受完全切除后的高风险黑色素瘤患者辅助治疗。8月19日，默沙东与Moderna宣布，Ⅲ期INTerpath-001临床试验取得积极顶线结果。该研究在1137例IIB-IV期高危黑色素瘤患者中开展，结果显示，与Keytruda单药治疗相比，V940联合Keytruda方案在无复发生存期（RFS）这一主要终点以及无远处转移生存期（DMFS）这一关键次要终点上均达到统计学显著性和具有临床意义的改善。这一结果被认为是个体化新抗原疗法以及mRNA肿瘤疫苗领域首次获得积极Ⅲ期临床结果，标志着该技术路线从早期探索进入更具商业化潜力的发展阶段。 然而，个性化肿瘤疫苗的发展仍面临制造、临床开发以及监管等多方面挑战，包括患者特异性生产模式带来的CMC复杂性、新抗原筛选和预测准确性、生产周期控制、临床评价体系建立以及规模化商业生产能力建设等。本文将简要介绍个性化肿瘤疫苗的优势与机遇，以及开发中的潜在挑战和应对措施。 多维策略提升个性化肿瘤疫苗的免疫激活能力 个性化肿瘤疫苗的核心价值在于通过精准识别患者肿瘤特异性新抗原，诱导针对性免疫反应。然而，由于肿瘤微环境通常具有较强的免疫抑制特征，仅依靠疫苗抗原本身往往难以产生足够强度和持续时间的抗肿瘤免疫。因此，目前进入临床开发阶段的个性化肿瘤疫苗通常并非作为单一疗法使用，而是通过佐剂增强、先进递送系统以及免疫联合治疗等策略，提高疫苗免疫原性并改善治疗效果。 佐剂是增强疫苗免疫反应的重要辅助成分。当其与抗原共同给药时，可以促进免疫细胞募集、增强抗原呈递细胞的活化，并进一步激发特异性T细胞免疫反应。对于肿瘤疫苗而言，仅包含抗原成分的“裸疫苗”通常难以有效诱导适应性免疫，尤其是在缺乏炎症刺激的肿瘤患者体内。根据作用机制不同，佐剂通常可分为两类：一类是抗原储存型佐剂，例如脂质体和乳剂，通过延长抗原释放时间提高免疫暴露；另一类是免疫刺激型佐剂，例如Toll样受体（TLR）激动剂，通过激活先天免疫通路增强后续适应性免疫反应。目前，部分佐剂平台已经实现临床应用，例如Montanide油包水乳剂系统，但更多针对肿瘤疫苗设计的新型佐剂仍处于研发阶段。 除佐剂外，高效递送系统也是提高个性化肿瘤疫苗效果的关键。尤其对于mRNA和DNA疫苗，由于核酸分子容易被体内核酸酶快速降解，无法以“裸露形式”直接进入细胞，因此需要借助纳米递送技术实现保护和靶向运输。近年来，脂质纳米颗粒（LNPs）成为mRNA疫苗最具代表性的递送平台。Moderna和Pfizer-BioNTech基于LNP技术成功开发COVID-19 mRNA疫苗，并进一步将相关经验应用于个性化肿瘤疫苗研发。此外，病毒样颗粒（VLPs）、脂质体等纳米材料也正在探索用于疫苗递送和免疫增强。 与此同时，个性化肿瘤疫苗与免疫检查点抑制剂（ICIs）的联合应用正在成为重要发展方向。肿瘤疫苗能够激活肿瘤特异性T细胞，提高免疫系统对肿瘤细胞的识别能力；而ICIs则可以解除肿瘤微环境中的免疫抑制，两者结合有望产生协同抗肿瘤效果。尤其对于传统免疫治疗响应较低的“冷肿瘤”，疫苗诱导的免疫激活可能帮助其转变为更易被免疫系统攻击的状态。 从实验室到临床应用：个性化肿瘤疫苗商业化道路上的多重挑战 尽管个性化肿瘤疫苗凭借精准靶向、免疫激活等优势展现出巨大的治疗潜力，但其从研发探索走向规模化应用仍面临来自生产制造、临床开发以及监管审批等多个环节的挑战。与传统“批量生产”的药物不同，个性化肿瘤疫苗需要针对每位患者独立设计和制造，这种高度定制化模式也对生物制药工艺、质量控制体系以及监管评价体系提出了新的要求。 CMC挑战：从个体化设计到稳定生产的工艺突破 化学、生产和质量控制（CMC）是个性化肿瘤疫苗开发中的核心挑战之一。其生产流程通常始于利用下一代测序技术对患者肿瘤样本进行分析，通过识别特异性新抗原，并结合计算机辅助设计技术完成疫苗序列设计。未来，人工智能（AI）和机器学习（ML）也有望进一步参与新抗原预测和疫苗设计过程。 然而，这些新兴技术的应用也带来了新的质量和监管要求。例如，NGS分析需要依赖经过验证的方法、符合要求的设备以及专业化人员操作；而AI/ML算法由于具有持续学习和优化能力，目前全球尚未形成统一的监管评价标准。研发企业需要在算法优化与数据一致性之间取得平衡，确保不同临床阶段以及不同患者之间的数据具有可比性，并在关键技术调整时与监管机构保持充分沟通。 此外，个性化肿瘤疫苗还面临产品放行相关挑战，包括效力检测、无菌检测和稳定性评价等。由于每位患者的疫苗产品均存在差异，传统基于标准产品建立的效力检测方法难以直接适用。因此，企业需要与监管机构共同探索更加灵活的评价策略。 在无菌检测方面，传统检测方法通常需要较长周期，可能影响个性化产品快速交付。目前，实时放行、参数放行、快速无菌检测以及“设计保证无菌”（sterility by design）等理念正在被探索，以降低生产周期并提高产品供应效率。 稳定性研究同样具有特殊性。由于个性化疫苗通常是在患者入组后才开始生产，因此企业需要通过工程批次、临床批次数据结合，以及针对不同产品特征设计稳定性研究方案，为产品质量提供支持。 非临床研究挑战：传统评价模式难以完全适用 由于每位患者的肿瘤具有独特性，每一种个性化肿瘤疫苗均为患者专属设计，传统依赖动物模型评价药代动力学（PK）、药效动力学（PD）和毒理学的方法难以直接应用。 目前，研究人员通常采用替代动物模型，例如接种特定肿瘤细胞的小鼠模型，并设计针对该模型新抗原的替代疫苗进行概念验证。这类研究能够提供一定的安全性和有效性信息，但其局限性也较为明显，因为动物模型评价的是替代产品，而非真正针对患者肿瘤设计的个体化疫苗。 毒理学研究同样面临类似问题。由于不同患者接受的疫苗组成不同，逐一开展完整毒理评价在实际操作中几乎不可行。此外，个性化肿瘤疫苗通常会联合使用佐剂，如果新型佐剂缺乏已有临床数据支持，则可能需要额外开展安全性研究。 临床开发挑战：患者选择、生产周期与治疗策略的平衡 如何选择最适合接受个性化肿瘤疫苗治疗的患者，是临床开发中的关键问题。许多肿瘤患者处于疾病晚期，并经历过多线治疗，其中化疗可能导致免疫功能下降。然而，疫苗发挥作用依赖于患者自身免疫系统，因此免疫状态不足可能影响治疗效果，甚至导致临床终点无法达到预期。 此外，个性化肿瘤疫苗的生产通常在患者入组后启动，从肿瘤样本采集、测序分析、疫苗设计到生产放行需要一定时间。即使当前先进平台已经能够显著缩短生产周期，患者在等待治疗过程中仍可能出现疾病进展。因此，如何优化生产流程，将制造周期控制在合理范围内，是实现临床应用的重要因素。 联合治疗方案也增加了临床设计复杂性。目前，个性化肿瘤疫苗通常与免疫检查点抑制剂等疗法联合使用。临床试验需要明确允许使用的伴随治疗方式，同时兼顾患者症状管理需求与试验数据可靠性。 在首次人体试验设计中，还需要综合考虑多个因素，包括： 疫苗剂量选择； 新抗原数量设计（目前临床研究通常包含约4–20个新抗原）； 免疫接种次数及时间间隔； 给药方式（如皮内、皮下或肌肉注射）； 佐剂选择及联合治疗策略； 后续加强免疫方案。 监管挑战：全球监管体系仍在不断探索 个性化肿瘤疫苗作为一种融合基因测序、核酸药物和精准医疗的新型疗法，其监管路径仍处于持续完善阶段。 在美国，美国食品药品监督管理局（FDA）通常将此类产品归类为治疗性肿瘤疫苗，并根据其具体特点进行监管评价。而在欧洲，相关产品主要依据组成成分进行分类，部分涉及核酸技术的产品可能被归入先进治疗药物产品（ATMPs）管理体系。随着监管政策的发展，未来更多核酸类肿瘤疫苗可能需要遵循ATMP相关法规要求。 在中国，国家药品监督管理局（NMPA）近年来持续完善细胞与基因治疗、核酸药物以及创新生物制品相关监管体系。对于个性化肿瘤疫苗而言，其涉及NGS检测、个体化设计、mRNA递送系统以及复杂生产流程等多个环节，未来可能需要结合疫苗、生物制品以及基因治疗产品的监管经验，建立更加适应个体化产品特点的评价体系。目前，中国相关企业和研究机构正在积极探索个性化肿瘤疫苗临床应用路径，监管科学体系也将在产品创新和临床需求推动下不断发展。 迈向精准抗肿瘤新时代：个性化肿瘤疫苗未来可期 个性化肿瘤疫苗正在推动肿瘤免疫治疗进入更加精准和个体化的发展阶段。尽管目前该领域仍面临生产制造、临床评价、毒理研究以及监管体系等多方面挑战，但以mRNA新抗原疫苗为代表的创新疗法已经展现出令人鼓舞的临床潜力，部分产品已进入后期临床试验阶段，并在特定患者群体中显示出改善疾病控制和降低复发风险的可能性。与此同时，大量处于早期研发阶段的新型肿瘤疫苗平台，也正在不断拓展其在实体瘤等难治性肿瘤中的应用边界。 未来，随着新抗原预测技术、人工智能辅助设计、mRNA递送平台、自动化生产工艺以及质量控制体系的持续优化，个性化肿瘤疫苗的开发效率和可及性有望进一步提升。同时，全球监管机构对于个体化生物制品评价体系的不断完善，也将为这类创新疗法的商业化应用提供更加清晰的发展路径。可以预见，个性化肿瘤疫苗将不仅是肿瘤免疫治疗领域的重要突破方向，也有望与免疫检查点抑制剂、细胞治疗等技术形成协同，为更多缺乏有效治疗选择的肿瘤患者带来更加精准、高效和持久的新型治疗方案，助力精准医疗迈向新的阶段。 随着个性化肿瘤疫苗向临床转化加速推进，稳定、高效的生物制造体系成为推动产品商业化的重要支撑。多宁生物依托一站式生物工艺平台，为mRNA及其他创新型疫苗产品开发提供全流程解决方案。通过高性能一次性技术、精准混配与缓冲液制备平台、高效下游纯化策略，以及符合GMP要求的工艺支持体系，多宁生物能够帮助客户优化研发与生产流程，提高工艺稳定性和产品一致性。从实验室探索到商业化生产，多宁生物致力于加速个性化肿瘤疫苗等前沿生物疗法的产业化进程，为精准医疗发展提供可靠的技术支撑。 中空纤维过滤器 多宁生物中空纤维过滤器凭借本地化服务、快速响应和高性价比，为生物制药企业提供可靠的分离纯化解决方案。膜材质采用亲水改性设计，吸附小、收率高，可有效保护生物大分子活性。标准化接口设计兼容市面上多品牌切向流过滤系统，操作简便、易于控制，工艺放大具有良好的线性。过滤器抗污染能力强、载量高，适用于从小试到工业化生产的多种工艺需求。丰富的规格选择，包括不同有效长度、膜孔径（MWCO）、纤维内径及膜材质，可满足超滤和微滤的多样化应用。此外，多宁生物提供稳定供货和完善技术支持，帮助客户快速完成工艺开发、优化及放大，实现高效生产和工艺稳定性。 一次性切向流管组 多宁生物一次性切向流管组可为基于中空纤维或平板膜包的切向流过滤（TFF）工艺专门设计，可结合现场使用的硬件系统进行定制化配置。管组可灵活整合不同形式过滤器、一次性隔膜泵泵头（如有）、特定泵管、导流板（如有）以及压力传感器、电导传感器等关键过程监测元件，满足不同工艺操作和过程监控需求。通过模块化和定制化设计，管组能够支持全程封闭式操作，简化工艺流程，确保无菌安全性，同时兼顾工艺的可控性和数据可追溯性，为实验室、中试及生产规模的 TFF 应用提供高效、可靠的解决方案。 DuoMix® 一次性落地式搅拌系统 多宁生物DuoMix®落地式搅拌系统覆盖从实验室数升规模到生产级数千升规模的应用需求，可灵活配置一次性搅拌袋，为mRNA药物及疫苗生产提供高效、可靠的配液解决方案。在mRNA工艺中，DuoMix®可用于转录反应缓冲液、层析平衡液、洗脱液、超滤浓缩缓冲液及LNP制剂相关溶液的配制，确保关键原辅料的一致性与稳定性。系统支持pH、电导、温度及称重等在线监测与控制，满足复杂工艺对精准配液和过程管理的要求。此外，DuoMix®还可作为中间液储存、样品暂存、切向流过滤（TFF）供液及收集容器等关键工艺单元，为mRNA生产流程提供灵活的一次性工艺支持，降低交叉污染风险并提升生产效率。 DuoWave®波浪式生物反应器 多宁生物DuoWave®波浪式生物反应器采用模块化设计，集成了高效的摇摆混合、控温及高精度传感功能，支持快速安装与参数闭环控制，其软件系统完全符合GMP与21 CFR Part 11法规要求。在mRNA生产中，DuoWave®的波浪式运动特性可为体外转录（IVT）提供卓越的混合效率与温和的剪切环境。这种低剪切力环境能够有效促进IVT反应中DNA模板、酶与核苷酸的均匀混合，确保反应动力学的稳定性，从而在提高mRNA产量的同时，降低因局部过热或剪切造成的产物降解，为制备高质量mRNA提供理想的反应平台。 参考文献： M.Shafique, K.C.Lal, M.F.Ahmed, Personalized cancer vaccines: promise, challenges, and the path forward. Ann. Med. Surg., 2025. P.Garg, R.Salgia, S.S.Singhal, mRNA-based cancer vaccines: A new frontier in personalized immunotherapy. Reviews on Cancer, 2026. L.Ye, G.Zhao, J.Ma, et al., Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics. Signal Transduction and Targeted Therapy, 2026. 关于多宁生物 上海多宁生物科技股份有限公司是一家中国领先的一站式生物工艺解决方案提供商，致力于提供生物制药产品从研发到商业化生产的综合解决方案，包括试剂及耗材、仪器设备、服务。公司主要运营生物工艺解决方案、实验室产品及服务两大业务线，通过一站式生物工艺体系帮助合作伙伴实现高效、稳定、质量及成本可控的药物研发及生产流程。 了解更多：www.duoningbio.com 媒体垂询：PR@duoningbio.com Cancer treatment is entering the era of precision immunotherapy. Following the successful global-scale application of mRNA technology through COVID-19 vaccines, an increasing number of innovative biopharmaceutical companies are exploring its new potential in oncology—the development of personalized cancer vaccines (PCVs). Unlike conventional vaccines designed as "one-size-fits-all" solutions, this emerging immunotherapy approach is based on each patient's unique tumor genomic profile. Through next-generation sequencing (NGS) and bioinformatics analysis, patient-specific tumor neoantigens are identified, and individualized vaccines are designed to precisely activate the immune system. The core mechanism is to induce antigen-specific T-cell immune responses, enabling the patient's own immune system to recognize and eliminate tumor cells while minimizing the impact on normal tissues. In recent years, the development of personalized cancer vaccines has gradually progressed from proof-of-concept studies toward clinical application. Among them, intismeran autogene (V940/mRNA-4157), an individualized mRNA neoantigen therapy jointly developed by Moderna and Merck, has become one of the most closely watched candidates in this field. The therapy is used in combination with the PD-1 immune checkpoint inhibitor Keytruda (pembrolizumab) as adjuvant treatment for high-risk melanoma patients after complete surgical resection. On August 19, Merck and Moderna announced that the Phase III INTerpath-001 clinical trial achieved positive topline results. The study was conducted in 1,137 patients with high-risk stage IIB-IV melanoma. Results showed that, compared with Keytruda monotherapy, the combination of V940 and Keytruda achieved statistically significant and clinically meaningful improvements in both the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS). These findings are considered the first positive Phase III clinical results for individualized neoantigen therapies and mRNA cancer vaccines, marking the transition of this technological approach from early-stage exploration toward a development stage with greater commercial potential. However, the development of personalized cancer vaccines still faces multiple challenges related to manufacturing, clinical development, and regulatory requirements. These include the CMC complexity associated with patient-specific manufacturing models, the accuracy of neoantigen identification and prediction, control of production timelines, establishment of clinical evaluation systems, and the development of scalable commercial manufacturing capabilities. This article briefly introduces the advantages and opportunities of personalized cancer vaccines, as well as the potential challenges and corresponding strategies during development. Multi-dimensional Strategies Enhance the Immune Activation Capability of Personalized Cancer Vaccines The core value of personalized cancer vaccines lies in their ability to precisely recognize patient-specific tumor neoantigens and induce targeted immune responses. However, because the tumor microenvironment is often highly immunosuppressive, relying solely on vaccine antigens is usually insufficient to generate strong and durable anti-tumor immunity. Therefore, personalized cancer vaccines currently entering clinical development are generally not used as standalone therapies, but rather combined with strategies such as adjuvant enhancement, advanced delivery systems, and immune combination therapies to improve vaccine immunogenicity and therapeutic efficacy. Adjuvants are important auxiliary components for enhancing vaccine-induced immune responses. When administered together with antigens, adjuvants can promote immune cell recruitment, enhance the activation of antigen-presenting cells, and further stimulate antigen-specific T-cell immune responses. For cancer vaccines, "naked vaccines" containing only antigen components often fail to effectively induce adaptive immunity, especially in tumor patients lacking sufficient inflammatory stimulation. Based on their mechanisms of action, adjuvants are generally divided into two categories. The first category includes antigen depot-forming adjuvants, such as liposomes and emulsions, which improve immune exposure by prolonging antigen release. The second category includes immune-stimulating adjuvants, such as Toll-like receptor (TLR) agonists, which enhance subsequent adaptive immune responses by activating innate immune pathways. Currently, some adjuvant platforms have already entered clinical application, such as the Montanide water-in-oil emulsion system, while more novel adjuvants specifically designed for cancer vaccines remain under development. In addition to adjuvants, efficient delivery systems are also critical for improving the efficacy of personalized cancer vaccines. Particularly for mRNA and DNA vaccines, nucleic acid molecules are easily degraded by nucleases in the body and cannot directly enter cells in their "naked" form. Therefore, nanotechnology-based delivery systems are required to provide protection and enable targeted transport. In recent years, lipid nanoparticles (LNPs) have become the most representative delivery platform for mRNA vaccines. Moderna and Pfizer-BioNTech successfully developed COVID-19 mRNA vaccines based on LNP technology and have further applied related experience to the development of personalized cancer vaccines. In addition, other nanomaterials, including virus-like particles (VLPs) and liposomes, are also being explored for vaccine delivery and immune enhancement. Meanwhile, the combination of personalized cancer vaccines with immune checkpoint inhibitors (ICIs) is emerging as an important development direction. Cancer vaccines can activate tumor-specific T cells and enhance the immune system's ability to recognize tumor cells, while ICIs can relieve immune suppression within the tumor microenvironment. The combination of these two approaches may generate synergistic anti-tumor effects. Particularly for "cold tumors", which typically show limited responses to conventional immunotherapies, vaccine-induced immune activation may help transform them into a state that is more susceptible to immune attack. From Laboratory Development to Clinical Application: Multiple Challenges on the Commercialization Pathway of Personalized Cancer Vaccines Although personalized cancer vaccines demonstrate significant therapeutic potential due to their advantages in precision targeting and immune activation, their transition from research and development to large-scale clinical application still faces challenges across multiple areas, including manufacturing, clinical development, and regulatory approval. Unlike traditional "batch-produced" medicines, personalized cancer vaccines require independent design and manufacturing for each patient. This highly customized model also places new demands on biopharmaceutical manufacturing processes, quality control systems, and regulatory evaluation frameworks. CMC Challenges: Process Breakthroughs from Individualized Design to Consistent Manufacturing Chemistry, manufacturing, and controls (CMC) represent one of the core challenges in the development of personalized cancer vaccines. The manufacturing process typically begins with the analysis of patient tumor samples using next-generation sequencing (NGS). By identifying patient-specific neoantigens and integrating computer-aided design technologies, vaccine sequences can be designed. In the future, artificial intelligence (AI) and machine learning (ML) are also expected to play increasingly important roles in neoantigen prediction and vaccine design. However, the application of these emerging technologies also introduces new quality and regulatory requirements. For example, NGS analysis relies on validated methods, compliant equipment, and specialized operators. Meanwhile, because AI/ML algorithms possess continuous learning and optimization capabilities, globally harmonized regulatory evaluation standards have not yet been established. Developers need to balance algorithm optimization with data consistency to ensure comparability of data across different clinical stages and among different patients, while maintaining sufficient communication with regulatory authorities when making key technological modifications. In addition, personalized cancer vaccines face challenges related to product release, including potency testing, sterility testing, and stability evaluation. Since each patient's vaccine product is unique, conventional potency assays developed for standardized products cannot be directly applied. Therefore, companies need to work together with regulatory agencies to explore more flexible evaluation strategies. For sterility testing, traditional methods often require extended testing periods, which may affect the rapid delivery of personalized products. Currently, approaches such as real-time release testing, parametric release, rapid sterility testing, and the concept of "sterility by design" are being explored to reduce manufacturing timelines and improve product availability. Stability studies also present unique challenges. Since personalized vaccines are typically manufactured only after patient enrollment, companies need to establish product quality through a combination of engineering batch data, clinical batch data, and stability study strategies designed according to specific product characteristics. Challenges in Nonclinical Studies: Traditional Evaluation Models Are Difficult to Fully Apply Because each patient's tumor has unique characteristics, every personalized cancer vaccine is specifically designed for an individual patient. As a result, traditional approaches relying on animal models to evaluate pharmacokinetics (PK), pharmacodynamics (PD), and toxicology cannot be directly applied. Currently, researchers typically use surrogate animal models, such as mouse models implanted with specific tumor cells, and design surrogate vaccines targeting neoantigens from these models for proof-of-concept studies. Such studies can provide certain safety and efficacy information; however, their limitations are also evident, as these animal models evaluate surrogate products rather than truly individualized vaccines designed based on patient-specific tumors. Toxicology studies face similar challenges. Since vaccine compositions vary among different patients, conducting complete toxicological evaluations for each individual product is practically infeasible. In addition, personalized cancer vaccines are often used in combination with adjuvants. If novel adjuvants lack sufficient clinical data support, additional safety studies may be required. Challenges in Clinical Development: Balancing Patient Selection, Manufacturing Timelines, and Treatment Strategies Selecting the patients most suitable for personalized cancer vaccine therapy is a key challenge in clinical development. Many cancer patients are diagnosed at advanced stages and have undergone multiple lines of treatment, including chemotherapy, which may impair immune function. However, vaccine efficacy relies on the patient's own immune system; therefore, insufficient immune competence may reduce treatment effectiveness or prevent clinical endpoints from being achieved. Furthermore, manufacturing of personalized cancer vaccines typically begins after patient enrollment. The entire process, including tumor sample collection, sequencing analysis, vaccine design, manufacturing, and product release, requires a certain amount of time. Even though advanced platforms have significantly shortened production timelines, patients may still experience disease progression while waiting for treatment. Therefore, optimizing manufacturing workflows and controlling production timelines within a reasonable range are critical factors for successful clinical implementation. Combination treatment strategies also increase the complexity of clinical trial design. Currently, personalized cancer vaccines are often administered in combination with immune checkpoint inhibitors and other therapies. Clinical trials need to define permitted concomitant treatments while balancing patient symptom management requirements with the reliability of trial data. In first-in-human clinical trial designs, multiple factors also need to be considered, including: Vaccine dose selection; Design of neoantigen numbers (current clinical studies generally include approximately 4–20 neoantigens); Number and interval of immunization doses; Route of administration (such as intradermal, subcutaneous, or intramuscular injection); Selection of adjuvants and combination treatment strategies; Subsequent booster immunization strategies. Regulatory Challenges: Global Regulatory Frameworks Are Still Evolving As a novel therapeutic approach integrating genomic sequencing, nucleic acid medicines, and precision medicine, personalized cancer vaccines are still undergoing continuous development of their regulatory pathways. In the United States, the U.S. Food and Drug Administration (FDA) generally classifies these products as therapeutic cancer vaccines and evaluates them based on their specific characteristics. In Europe, related products are primarily classified according to their components, and some nucleic acid-based products may fall under the regulatory framework for Advanced Therapy Medicinal Products (ATMPs). As regulatory policies continue to evolve, more nucleic acid-based cancer vaccines may need to comply with ATMP-related regulatory requirements in the future. In China, the National Medical Products Administration (NMPA) has continuously improved regulatory frameworks for cell and gene therapies, nucleic acid medicines, and innovative biological products in recent years. For personalized cancer vaccines, which involve multiple aspects including NGS testing, individualized design, mRNA delivery systems, and complex manufacturing processes, future evaluation systems may need to integrate regulatory experiences from vaccines, biological products, and gene therapy products to better accommodate the characteristics of personalized therapies. Currently, Chinese companies and research institutions are actively exploring clinical development pathways for personalized cancer vaccines, and the regulatory science framework is expected to continue evolving under the combined influence of product innovation and clinical demand. Towards a New Era of Precision Cancer Treatment: The Future of Personalized Cancer Vaccines Holds Great Promise Personalized cancer vaccines are driving cancer immunotherapy toward a more precise and individualized development stage. Although this field still faces multiple challenges in manufacturing, clinical evaluation, toxicology studies, and regulatory frameworks, innovative therapies represented by mRNA neoantigen vaccines have already demonstrated encouraging clinical potential. Some products have entered late-stage clinical trials and have shown the potential to improve disease control and reduce the risk of recurrence in specific patient populations. Meanwhile, numerous novel cancer vaccine platforms in early-stage development are continuously expanding their potential applications in difficult-to-treat cancers, including solid tumors. In the future, with continued advancements in neoantigen prediction technologies, artificial intelligence-assisted design, mRNA delivery platforms, automated manufacturing processes, and quality control systems, the development efficiency and accessibility of personalized cancer vaccines are expected to further improve. At the same time, the continuous refinement of evaluation frameworks for individualized biologics by global regulatory agencies will provide a clearer pathway for the commercialization of these innovative therapies. It is foreseeable that personalized cancer vaccines will not only represent an important breakthrough direction in cancer immunotherapy but may also establish synergistic effects with technologies such as immune checkpoint inhibitors and cell therapies, providing more precise, effective, and durable treatment options for cancer patients with limited therapeutic choices, and advancing precision medicine into a new stage. As personalized cancer vaccines continue to accelerate toward clinical translation, robust and efficient biomanufacturing systems have become critical enablers for product commercialization. Leveraging its one-stop bioprocessing platform, Duoning provides comprehensive solutions for the development of mRNA and other innovative vaccine products. Through high-performance single-use technologies, precise formulation and buffer preparation platforms, efficient downstream purification strategies, and GMP-compliant process support systems, we help customers optimize research and manufacturing workflows, improve process robustness, and enhance product consistency. From laboratory exploration to commercial-scale production, we are committed to accelerating the industrialization of cutting-edge biologics such as personalized cancer vaccines and providing reliable technological support for the advancement of precision medicine. Hollow Fiber Filters Duoning Biotech hollow fiber filters provide reliable separation and purification solutions for biopharmaceutical companies through localized services, rapid response, and high cost-effectiveness. The membrane materials feature a hydrophilic modification design, offering low adsorption and high recovery rates to effectively protect the activity of biological macromolecules. The standardized interface design is compatible with multiple brands of tangential flow filtration (TFF) systems available on the market, enabling simple operation, easy process control, and excellent linear scalability during process scale-up. The filters feature strong fouling resistance and high loading capacity, making them suitable for a wide range of process requirements from small-scale development to industrial production. A comprehensive selection of specifications, including different effective lengths, pore sizes (MWCO), inner diameters, and membrane materials, is available to meet diverse ultrafiltration and microfiltration applications. In addition, we provide stable supply capabilities and comprehensive technical support to help customers rapidly complete process development, optimization, and scale-up, achieving efficient production and robust process performance. Single-use TFF Assemblies Single-use tangential flow filtration assemblies from Duoning are specifically designed for TFF processes based on hollow fiber filters or flat-sheet cassettes and can be customized according to the hardware systems used at the customer site. The assemblies can flexibly integrate different types of filters, single-use diaphragm pump heads (if applicable), dedicated pump tubing, insert plates (if applicable), as well as critical process monitoring components such as pressure sensors and conductivity sensors, meeting diverse process operation and monitoring requirements. Through modular and customized designs, the assemblies support fully closed processing, simplify process workflows, ensure aseptic safety, and simultaneously maintain process controllability and data traceability. They provide efficient and reliable solutions for TFF applications at laboratory, pilot, and manufacturing scales. DuoWave® Wave-type Single-Use Bioreactor DuoWave® wave-type bioreactor adopts a modular design integrating efficient rocking mixing, temperature control, and high-precision sensing functions. It supports rapid installation and closed-loop parameter control, while its software system fully complies with GMP and 21 CFR Part 11 regulatory requirements. In mRNA manufacturing, the rocking motion characteristics of DuoWave® provide excellent mixing efficiency and a gentle shear environment for in vitro transcription (IVT) processes. This low-shear environment effectively promotes the uniform mixing of DNA templates, enzymes, and nucleotides during IVT reactions, ensuring stable reaction kinetics. As a result, it helps improve mRNA yield while reducing product degradation caused by localized overheating or shear stress, providing an ideal reaction platform for the production of high-quality mRNA. References: M.Shafique, K.C.Lal, M.F.Ahmed, Personalized cancer vaccines: promise, challenges, and the path forward. Ann. Med. Surg., 2025.  P.Garg, R.Salgia, S.S.Singhal, mRNA-based cancer vaccines: A new frontier in personalized immunotherapy. Reviews on Cancer, 2026. L.Ye, G.Zhao, J.Ma, et al., Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics. Signal Transduction and Targeted Therapy, 2026. Shanghai Duoning Biotechnology Co., Ltd. Is a leading one-stop bioprocess solutions provider, dedicated to offering comprehensive solutions for biopharmaceutical products from R&D to commercial manufacturing, including reagents and consumables, instruments and equipment, and services. The company primarily operates two business segments: bioprocess solutions and laboratory products & services. Through its one-stop bioprocess platform, we help partners achieve efficient, stable, and cost- and quality-controlled drug development and manufacturing processes. Learn more: www.duoningbio.com Media: PR@duoningbio.com Swipe left/right to switch languages (CN/EN)